Bank of America’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-113,092
| Closed | -$815K | – | 6669 |
|
|
2025
Q4 | $815K | Buy |
113,092
+99,023
| +704% | +$801K | ﹤0.01% | 4644 |
|
|
2025
Q3 | $144K | Buy |
14,069
+136
| +1% | +$1.53K | ﹤0.01% | 6434 |
|
|
2025
Q2 | $145K | Buy |
13,933
+7,952
| +133% | +$84.7K | ﹤0.01% | 6335 |
|
|
2025
Q1 | $78.8K | Sell |
5,981
-5,709
| -49% | -$102K | ﹤0.01% | 6592 |
|
|
2024
Q4 | $209K | Buy |
11,690
+4,120
| +54% | +$83.4K | ﹤0.01% | 6095 |
|
|
2024
Q3 | $122K | Buy |
7,570
+2,314
| +44% | +$36.2K | ﹤0.01% | 6240 |
|
|
2024
Q2 | $142K | Buy |
5,256
+4,053
| +337% | +$96.7K | ﹤0.01% | 6068 |
|
|
2024
Q1 | $23.5K | Sell |
1,203
-5,193
| -81% | -$110K | ﹤0.01% | 6722 |
|
|
2023
Q4 | $132K | Buy |
6,396
+3,490
| +120% | +$104K | ﹤0.01% | 6263 |
|
|
2023
Q3 | $92.4K | Buy |
2,906
+701
| +32% | +$23.4K | ﹤0.01% | 6276 |
|
|
2023
Q2 | $74.1K | Sell |
2,205
-1,054
| -32% | -$37.7K | ﹤0.01% | 6321 |
|
|
2023
Q1 | $136K | Buy |
3,259
+1,620
| +99% | +$76.2K | ﹤0.01% | 6123 |
|
|
2022
Q4 | $55.6K | Sell |
1,639
-1,022
| -38% | -$43.5K | ﹤0.01% | 6443 |
|
|
2022
Q3 | $131K | Buy |
2,661
+614
| +30% | +$33.7K | ﹤0.01% | 6212 |
|
|
2022
Q2 | $80K | Sell |
2,047
-1,081
| -35% | -$32K | ﹤0.01% | 6593 |
|
|
2022
Q1 | $115K | Sell |
3,128
-1,616
| -34% | -$101K | ﹤0.01% | 6782 |
|
|
2021
Q4 | $464K | Buy |
4,744
+4,232
| +827% | +$455K | ﹤0.01% | 5939 |
|
|
2021
Q3 | $64K | Buy |
512
+135
| +36% | +$16.3K | ﹤0.01% | 6933 |
|
|
2021
Q2 | $47K | Sell |
377
-2,706
| -88% | -$322K | ﹤0.01% | 6867 |
|
|
2021
Q1 | $418K | Buy |
3,083
+2,154
| +232% | +$267K | ﹤0.01% | 5519 |
|
|
2020
Q4 | $85K | Sell |
929
-312
| -25% | -$27.1K | ﹤0.01% | 6067 |
|
|
2020
Q3 | $92K | Sell |
1,241
-972
| -44% | -$74.5K | ﹤0.01% | 5751 |
|
|
2020
Q2 | $189K | Sell |
2,213
-1,983
| -47% | -$180K | ﹤0.01% | 5285 |
|
|
2020
Q1 | $303K | Buy |
4,196
+3,265
| +351% | +$315K | ﹤0.01% | 4844 |
|
|
2019
Q4 | $66K | Sell |
931
-189
| -17% | -$9.12K | ﹤0.01% | 6171 |
|
|
2019
Q3 | $59K | Sell |
1,120
-1,644
| -59% | -$87.4K | ﹤0.01% | 6254 |
|
|
2019
Q2 | $148K | Buy |
2,764
+2,166
| +362% | +$148K | ﹤0.01% | 5800 |
|
|
2019
Q1 | $43K | Buy |
598
+228
| +62% | +$14.4K | ﹤0.01% | 6256 |
|
|
2018
Q4 | $29K | Buy |
370
+232
| +168% | +$52.9K | ﹤0.01% | 6391 |
|
|
2018
Q3 | $64K | Buy |
138
+37
| +37% | +$14.9K | ﹤0.01% | 6099 |
|
|
2018
Q2 | $40K | Buy |
101
+65
| +181% | +$23.1K | ﹤0.01% | 6251 |
|
|
2018
Q1 | $11K | Sell |
36
-19
| -35% | -$5.41K | ﹤0.01% | 6589 |
|
|
2017
Q4 | $16K | Buy |
55
+33
| +150% | +$14.4K | ﹤0.01% | 6492 |
|
|
2017
Q3 | $12K | Buy |
22
+21
| +2,100% | +$11.2K | ﹤0.01% | 6474 |
|
|
2017
Q2 | $0 | Sell |
1
-29
| -97% | -$12.8K | ﹤0.01% | 7132 |
|
|
2017
Q1 | $13K | Buy |
30
+7
| +30% | +$2.94K | ﹤0.01% | 6463 |
|
|
2016
Q4 | $12K | Buy |
23
+17
| +283% | +$9.93K | ﹤0.01% | 6501 |
|
|
2016
Q3 | $3K | Buy |
+6
| New | +$2.35K | ﹤0.01% | 6739 |
|
Other funds holding RNAC
VCM
6CM
EAM
Bank of America's RNAC Position: Q1 2026 in Review
Bank of America sold out of Cartesian Therapeutics (RNAC) in Q1 2026, closing a stake of 113,092 shares — an estimated $815K sold.
Bank of America first reported a position in RNAC in Q3 2016 and held it in 38 quarters. The position peaked at $815K in Q4 2025. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.
- Bank of America reported no remaining Cartesian Therapeutics position as of Q1 2026 after selling out during the quarter.
- Bank of America sold 113,092 Cartesian Therapeutics shares in Q1 2026, an estimated $815K.
- Bank of America first reported a position in Cartesian Therapeutics in Q3 2016 and held it in 38 quarters.
- Bank of America's Cartesian Therapeutics position peaked at $815K in Q4 2025.
- 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.